drugset / Trial / NCT05929248
Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus and refractory thrombocytopenia
Timeline
- Start
- 2023-07-01
- Primary completion
- 2024-06-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Background | AZA | Unknown | — | — |
| Background | CTX | Unknown | — | — |
| Background | CsA | Unknown | — | — |
| Background | HCQ | Unknown | — | — |
| Background | LEF | Unknown | — | — |
| Background | MMF | Unknown | — | — |
| Background | MTX | Unknown | — | — |
| Background | SASP | Unknown | — | — |
| Background | Tacrolimus | Small molecule | — | — |